John S. Montalbano
Known title: DirectorCIK: 0001834423
John S. Montalbano's purchase track record
How the stock did after each of John S. Montalbano's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 7 since August 16, 2021
Stock higher 6 months later
60%
3 months: 33%
Median 6-month return
+17.9%
3 months: -3.8%
Beat the S&P 500
60%
median +25.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/18/2026 | ABCL | $110K | pending | pending | — |
| 5/14/2026 | ABCL | $95K | +149.7% | pending | — |
| 11/26/2025 | ABCL | $178K | -12.4% | +49.5% | +10.4% |
| 3/6/2025 | ABCL | $198K | -0.4% | +74.8% | +13.3% |
| 11/6/2023 | ABCL | $137K | +10.6% | -8.2% | +18.7% |
| 3/1/2022 | ABCL | $266K | -15.7% | +17.9% | -7.4% |
| 8/16/2021 | ABCL | $103K | -7.2% | -46.2% | -1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ABCL | ▲ Buy | Open Market | 10,000 | $110K | 8/18/2026 | View on chart |
| ABCL | ▲ Buy | Open Market | 20,000 | $95K | 5/14/2026 | View on chart |
| ABCL | ▲ Buy | Open Market | 50,000 | $178K | 11/26/2025 | View on chart |
| ABCL | ▲ Buy | Open Market | 25,000 | $57K | 3/10/2025 | View on chart |
| ABCL | ▲ Buy | Open Market | 60,000 | $141K | 3/6/2025 | View on chart |
| ABCL | ▲ Buy | Open Market | 10,000 | $45K | 11/8/2023 | View on chart |
| ABCL | ▲ Buy | Open Market | 20,000 | $93K | 11/6/2023 | View on chart |
| ABCL | ▲ Buy | Open Market | 10,000 | $85K | 3/4/2022 | View on chart |
| ABCL | ▲ Buy | Open Market | 20,000 | $181K | 3/1/2022 | View on chart |
| ABCL | ▲ Buy | Open Market | 6,000 | $103K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results
UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results. UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.